Innorna: Presented new data on mRNA-LNP therapies for PFIC2 and Wilson’s Disease at ASGCT 2025. University of Nottingham, MIT, Sail Biomedicines: Developed cryogenic mass spectrometry to analyze LNP surface structures. Sail Biomedicines: Announced preclinical data on in vivo eRNA CAR-T candidate SAIL-0804 for autoimmune diseases. Arcturus Therapeutics: SWOT analysis highlighted LNP platform advancements and pipeline progress. ResearchAndMarkets.com: Reported mRNA platform